Consolidated Statements of Operations (Unaudited) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Revenues:
Product sales	$ 30,359	$ 34,357
Contracts and grants	12,741	15,954
Total revenues	43,100	50,311
Operating expenses:
Cost of product sales	5,698	7,511
Research and development	30,724	26,246
Selling, general and administrative	20,028	19,492
Impairment of in-process research and development	0	9,600
Loss from operations	(13,350)	(12,538)
Other income (expense):
Interest income	23	25
Interest expense	(11)	(3)
Other income (expense), net	17	854
Total other income (expense)	29	876
Loss before benefit from income taxes	(13,321)	(11,662)
Benefit from income taxes	(4,516)	(3,640)
Net loss	(8,805)	(8,022)
Net loss attributable to noncontrolling interest	743	1,193
Net loss attributable to Emergent BioSolutions Inc.	$ (8,062)	$ (6,829)
Loss per share - basic	$ (0.22)	$ (0.19)
Loss per share - diluted	$ (0.22)	$ (0.19)
Weighted-average number of shares - basic	35,968,064	36,045,839
Weighted-average number of shares - diluted	35,968,064	36,045,839